An Assay that Predicts In Vivo Efficacy for DNA Aptamers that Stimulate Remyelination in a Mouse Model of Multiple Sclerosis. Mol Ther Methods Clin Dev 2018 Jun 15;9:270-277
Date
05/01/2018Pubmed ID
29707601Pubmed Central ID
PMC5918178DOI
10.1016/j.omtm.2018.03.005Scopus ID
2-s2.0-85045699819 (requires institutional sign-in at Scopus site) 5 CitationsAbstract
Multiple sclerosis (MS) is a debilitating disease for which regenerative therapies are sought. We have previously described human antibodies and DNA aptamer-streptavidin conjugates that promote remyelination after systemic injection into mice infected by Theiler's murine encephalomyelitis virus. Here, we report an in vitro assay of myelin binding with results that correlate with remyelination outcome in vivo, as shown for data from a set of DNA aptamer complexes of different size and formulation. This in vitro assay will be valuable for future screening of MS regenerative therapies targeting remyelination.
